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 Abstract 
 
Rationale Treatment resistant depression is a common clinical problem, often 
complicated with suicidal ideations and greater lifetime functional impairment, and 
represents a considerable challenge to management and treatment.  
Objective The aim of a prospective, open-label, non-comparative, flexible-dosed 20-week 
study was to evaluate the effects of quetiapine, as an add-on therapy, in patients with 
treatment resistant depression who were refractory to previous treatments.  
Method Fourteen patients with major depressive disorder (DSM-IV criteria) were treated 
for 20 weeks with quetiapine (mean dose 315 ± 109 mg/day). Patients were evaluated at 
baseline, and weekly from 1-9 week, and than after 12, 16 and 20 weeks of treatment, 
using Hamilton Rating Scale for Depression-17 items (HAMD) scale.  
Results Fourteen patients with treatment resistant depression completed the 20-week open 
trial with quetiapine. The augmentation with quetiapine significantly reduced total scores 
and scores listed in the anxiety and insomnia subscales on the HAMD, and these effects 
were observed after the first week of treatment. Quetiapine add-on treatment significantly 
decreased the scores listed in the depressive mood on the HAMD subscale after fourth 
week of treatment.  
Conclusions Our preliminary data indicate that quetiapine add-on therapy appears to have 
beneficial effects in the treatment of patients with treatment resistant depression, with the 
rapid and sustained improvement in insomnia and anxiety. 
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Introduction 
  
Treatment resistant depression is a common clinical problem, frequently 
associated with the greater suicidal ideation and attempts during the current episode, and 
the greater lifetime functional impairment (Malhi et al. 2005). Although there are many 
effective treatments for a depressive episode, the management of treatment resistant 
depression continues to represent a considerable challenge to the psychiatrists. There are 
a few comparative data regarding the treatment options for treatment resistant depression 
(Kennedy and Lam 2003), because treatment resistant depression represents an exclusion 
criteria for the most antidepressant clinical trials (Dodd et al. 2005).  
Quetiapine is an atypical antipsychotic with a unique receptor binding profile: it 
has moderate affinity for 5-HT2A serotonergic, α1-adrenergic, muscarinic and 
histaminergic receptors, only a minor affinity for dopamine D2 and 5-HT1A receptor and 
a low affinity for 5-HT2C, α2-adrenergic and D1 receptors (DeVane and Nemeroff 
2001). It possesses a positive effect on the depressive mood in patients with 
schizophrenia (Kasper 2004) and bipolar disorder (Calabrese et al. 2005). While atypical 
antipsychotics have been successfully applied in the treatment resistant depression 
(Nemeroff 2005), there are only a few data regarding the efficacy of quetiapine in 
treatment resistant depression. Since one study retrospectively investigated the efficacy of 
quetiapine in treatment resistant depression in 10 adolescents (Pathak et al. 2005), and the 
other study assessed the augmentation of quetiapine to sertraline in the naturalistic case 
series outcome in 6 patients with treatment resistant depression (Devarajan et al. 2006), 
the aim of our study was to evaluate the efficacy and safety of quetiapine augmentation in 
the treatment resistant adult inpatients with major depressive disorder who were resistant 
to multiple antidepressant trials. We hypothesized that adding quetiapine to the current 
antidepressants would be a well-tolerated and effective treatment of treatment resistant 
depression. 
 
Materials and methods 
Subjects 
This was a prospective, open-labelled, non-comparative, flexible-dosed study that lasted 
20 weeks. Patients (N=18) with major depressive disorder (diagnosis was made using 
structured clinical interview for DSM-IV disorders (American Psychiatric Association 
1994) were recruited consecutively from the inpatients from the Department of 
Psychiatry of the Clinical Hospital Centre Zagreb, and 14 patients finished the study. All 
patients have signed informed consent document, approved by the local Ethic Committee, 
prior to inclusion. The following inclusion criteria were used: a) age ≥ 18 years; b) 
patients with major depressive disorder, who have failed at least two antidepressant trials 
of different classes (Annath 1998), with a minimum HAMD-17 cut-off scores of 20; c) 
patients who have failed the mood stabilizer augmentation trial were also included. The 
exclusion criteria were: a) psychoactive use disorder within the previous 6 months; b) 
diagnosis of schizophrenia, schizoaffective disorder, dementia, posttraumatic stress 
disorder, bipolar I and bipolar II disorder using; c) presence of psychotic features 
(determined as the presence of either delusions or hallucinations in clinical interview, as 
specified in DSM-IV); d) treatment with any antipsychotics for the current depressive 
episode; e) pregnant or nursing women, or women in risk of becoming pregnant; f) 
duration of current depressive episode for less than 2 years, to exclude chronic 
depression. Comorbid chronic medical conditions were not the exclusion criteria, except 
the life-threatening conditions. Quetiapine was added to the current antidepressant 
treatment according to the usual dose-titration recommendation (the starting dosage was 
50 mg at bedtime). The dosage was increased in 50 mg increments daily, up to the 
individual target dose. The target dose was determined according to the safety and 
tolerability. The mean quetiapine dose was 315 ± 109 mg/day. All patients have 
continued taking their current antidepressant treatment regimen within the current dose-
range. Antidepressants given in combination with quetiapine were: reboxetine + 
paroxetine (3 patients), reboxetine + sertraline (1 patient), fluvoxamine (2 patients), 
sertraline (1 patient), paroxetine (2 patients), paroxetine + maprotiline (4 patients), 
moclobemide (1 patient). Symptomatic benzodiazepine treatment in flexible dose range 
was allowed. Depressive symptoms were measured by Hamilton Rating Scale for 
Depression-17 items (HAMD) (Hamilton 1960). Total HAMD scores and the scores in 
the depressive mood subscale (item 1), insomnia subscale (items 4, 5 and 6), anxiety 
subscale (items 10 and 11) on the HAMD scores were evaluated at baseline, weekly 
during first 9 weeks of treatment, and monthly thereafter (i.e. after 1, 2, 3, 4, 5, 6, 7, 8, 9, 
12, 16 and 20 weeks of quetiapine treatment). Response was defined as a 50% or greater 
reduction of the baseline HAMD scores. In addition to antidepressants, 3 patients were 
currently treated with carbamazepine, and 2 patients received also lamotrigine. 
Concomitant medical conditions in patient treated quetiapine were: hyperlipidemia in 4 
patients, arterial hypertension in 5 patients, ulcer disease in 2 patients, Parkinson’s 
disease in 2 patients, hypothyroids in 2 patients, and rheumatoid arthritis or coronary 
artery disease or psoriasis vulgaris in 1 patient. 
Among responders, 3 patients had hypotension, and 2 patients had daytime 
sedation, which were transient and mild in all cases. There were no serious adverse 
events. 
 
Statistical analysis 
Statistical evaluation of the results, expressed as means ± standard deviations (SD), 
was performed using Friedman repeated measures one-way analysis of variance 
(RMANOVA) and Dunnett’s test. The treatment effect was evaluated with RMANOVA, 
and Dunnett’s test compared the treatment scores achieved after 1-20 weeks of treatment 
with the baseline scores.The significance was accepted when p<0.05. All calculations 
were made with the statistical program Sigmastat (Jandel, version 2, Jandel Corp., USA). 
 
Results 
Demographic and clinical characteristics of patients are presented in Table 1. From the 18 
patients, 14 patients have responded to add-on quetiapine treatment. One patient has 
dropped out from the study due to the persistent hypotension and 3 patients have dropped 
out due to the lack of response to quetiapine. 
Fourteen patients with treatment resistant depression completed the 20-week open 
trial with quetiapine. Quetiapine add-on treatment for 1-20 weeks significantly [χ2 
=161.4; df=12; p<0.001] reduced the total scores on the HAMD scale (Figure 1) in 
patients, and this rapid effect was observed from the first week of treatment in all 14 
patients. However, the 50% reduction of the total HAMD scores was achieved after the 
sixth week of treatment (Table 1). Quetiapine significantly [χ2 =136.0; df=12; p<0.001] 
decreased the scores on the HAMD-insomnia subscale (items 4, 5 and 6) after 1-20 weeks 
of treatment, and this fast effect was significant also from the first week of treatment 
(Figure 2). A significant [χ2 =156.9;df=12; p<0.001] response to quetiapine was observed 
in the HAMD-depressive mood subscale (item 1) after 4-20 weeks of treatment, where 
depressed mood scores were significantly reduced after the fourth week of quetiapine 
treatment (Figure 3). The anxiety scores on the HAMD (items 10 and 11) were 
significantly [χ2 =158.2; df=12;  p<0.001] lower after  the second week of treatment than 
at baseline (Figure 4), and stayed lower from 2-20 weeks of treatment. 
 
Discussion  
 
The add-on quetiapine treatment improved the clinical state in adult patients with 
treatment resistant depression. The study was performed in naturalistic setting with the 
wide inclusion criteria. Most of our patients, due to their substantial burden of medical 
comorbidity, past suicide attempts, multiple drug resistance and concomitant medical 
treatment, would not be able to fulfil the inclusion criteria in the typical randomized, 
double-blind clinical trials. It has been questioned recently (Tandon and Jibsen 2003) 
whether the results of the formal clinical randomized, double-blind clinical trials might be 
applied to these refractory patients, who are, in turn, frequently present in the clinical 
practice, and the most difficult to treat. The increasing body of evidence suggests that 
atypical antipsychotics are effective in treatment resistant depression (Hirose and Ashby 
2002; Simon and Nemeroff 2005). The data from our study confirm this hypothesis 
(Nemeroff 2005), and extend it with the data showing beneficial effects of another 
atypical antipsychotic, quetiapine, as an add-on therapy, which showed promise as a safe 
and effective therapeutic strategy for patients with difficult-to-treat major depression. 
The efficacy of quetiapine was investigated using  retrospectively evaluated charts 
of adolescents up to 18 years of age who have failed to respond to an 8-week treatment 
with selective serotonin reuptake inhibitors (SSRIs), and 7 out of 10 adolescents 
responded to quetiapine (Pathak et al. 2005). A clinical efficacy of quetiapine 
augmentation to sertraline has been shown, and quetiapine addition has improved the 
HAMD-21 rating scores and outcome in 6 patients with treatment resistant depression 
during 5-6 weeks (Devarajan et al. 2006). The results from our study, obtained on the 
larger group of patients, treated for the longer period (20 weeks) with add-on quetiapine, 
agree with these results. We have observed a rapid overall response of adult patients with 
treatment resistant depression to quetiapine augmentation. In our study, from 18 patients 
which were enrolled, 14 patients were responders, as shown in significantly reduced 
HAMD total and subscale scores. Other 4 patients dropped out due to the persistent 
hypotension and the lack of response to quetiapine, hence their data were excluded from 
the study. The response to quetiapine, defined as 50% reduction of the baseline HAMD-
17 scores, was achieved in the majority of patients after 6 weeks (between 4 and 8 week) 
of treatment. In agreement with the clinically relevant reduction in depressive and anxiety 
symptoms in 11 patients with different anxiety disorders (Adson et al. 2004), quetiapine 
augmentation in our study significantly decreased total scores and scores listed in the 
anxiety and insomnia subscales on the HAMD, and these rapid effects were observed 
after first week of treatment. In line with the reported beneficial effects of quetiapine on 
depressive symptomatology, aggression, hostility, mania, anxiety, delirium and 
posttraumatic stress disorder (PTSD) (Adityanjee and Schulz 2002, Nemeroff et al. 
2002), anxiety disorders (Adson et al. 2004), and in treatment resistant depression 
(Devarajan et al. 2006), we have found that quetiapine, added to the current 
antidepressant treatment, significantly reduced the scores listed in the depressive mood 
on the HAMD subscale after fourth week of treatment.  
Sleep disturbances are common and severe symptoms in depression. While the 
efficacy of SSRIs in the treatment of depression is beyond doubt, SSRIs are not so 
effective in the treatment of insomnia. Addition of quetiapine to a stable dose of a SSRI 
resulted in the significant reduction of early and middle insomnia in 11 patients with 
anxiety disorders after 2 weeks of quetiapine treatment (Adson et al. 2004). The mean 
quetiapine dose in that study was 180 mg/day (Adson et al. 2004), which is twice lower 
than the dose used in our study. Given the diagnoses of generalized anxiety disorders, 
and/or unipolar depression and dysthymia in the former study (Adson et al. 2004), it 
might be suggested that our patients with treatment resistant depression were more 
severely disabled, and therefore they required the higher doses of quetiapine to achieve a 
similar reduction of the symptoms. of atypicals on sleep in depression, the papers of 
Sharpley et al (Journal of Clinical Psychiatry 66 (4), pp. 450-454 and Journal of 
Clinical Psychiatry 64 (2), pp. 192-196) Quetiapine, olanzapine and risperidone were 
found to improve subjective sleep quality in patients with schizophrenia (Yamashita 
et al. 2005), and quetiapine (Roberts et al. 2005; Kozaric-Kovacic and Pivac 2006) 
and olanzapine (Jakovljević et al. 2003) rapidly improved insomnia and nightmares 
in combat-related PTSD mijenjati. Atypical antipsychotic drugs possess sleep-
improvement properties across the diagnoses. Low dose of quetiapine (25 to 100 mg) has 
improved sleep quality in healthy volunteers (Cohrs et al. 2004). Sleep-improving 
properties of quetiapine might be achieved by its antihistaminergic (H1 receptors), 
dopaminergic (D1 receptors) and the α1-adrenergic receptors blocking properties. 
On the other hand, the mechanism by which quetiapine’s addition into the current 
antidepressant treatment improved depressive symptoms in treatment resistant depression 
is still not clear, although quetiapine shows efficacy in treating depressive symptoms in 
different psychiatric illnesses (Kasper 2003). The well-established antipsychotic efficacy 
of quetiapine does not explain the improvement of depression observed in the present and 
previous (Pathak et al. 2005) study, because these patients were not psychotic. However, 
the combination of quetiapine and other antidepressant/s might have improved untreated 
residual psychopathology of these patients (Deverajan et al., 2006). Quetiapine targets 
different neurotransmitter receptors (DeVane and Nemeroff 2001), that interact with each 
other and affect brain regions involved in the regulation of anxiety and mood. In addition, 
quetiapine was found to down-regulate the activity of the hypothalamic-pituitary-adrenal 
(HPA) axis in healthy male volunteers (Cohrs et al. 2006). An over-activity of HPA axis 
is a characteristic feature of major depression, and although we did not study the HPA 
axis activity in our treatment resistant depression patients, we might assume that they 
have a hyperactive HPA axis. Hence the beneficial antidepressant effect of quetiapine 
augmentation might be achieved via a down-regulation of the HPA axis. 
The study has several limitations such as the small number of patients, open-
labelled design, and the fact that quetiapine concentration was not measured and therefore 
the pharmacokinetic interaction with antidepressants cannot be ruled. However, its 
advantage was in a prolonged (20-week) treatment, an add-on therapy with quetiapine, 
and in inclusion of the treatment resistant patients with major depression.  
In conclusion, the preliminary data on the quetiapine add-on therapy appear to 
have beneficial effects in patients with treatment resistant depression, and quetiapine 
augmentation showed rapid and sustained improvement in insomnia and anxiety.  
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 Table 1. Demographic and clinical characteristics (means ± SD) in patients with 
treatment resistant depression 
Age (years) 54.0 ± 11.7 
Male: female ratio 10:4 
Number of patients with at least 1 suicide attempt 9 
Duration of current depressive episode (months) 11.1 ± 8.1 
Number of antidepressants given to threat the current 
episode  
3.77 ± 1.16 
HAMD total score at baseline 39.14 ± 2.14 
50% reduction of the HAMD total score 16.64 ± 1.50 
Week when a 50% fall of HAMD was achieved 6.21 ±  0.98 
 
 
Legend to the Figures: 
 
Figure 1. Total scores (mean ± SD) in Hamilton Rating Scale for Depression (HAMD)  in 
patients with treatment resistant depression at baseline, during and after 20 weeks of 
treatment with quetiapine.  
*differences from the baseline scores, p<0.05. 
 
Figure 2. Insomnia scores (mean ± SD) in Hamilton Rating Scale for Depression 
(HAMD: items 4, 5 and 6: insomnia early,  middle and late) in patients with treatment 
resistant depression at baseline, during and after 20 weeks of treatment with quetiapine.  
*differences from the baseline scores, p<0.05. 
 
Figure 3. Depressed mood scores (mean ± SD) in Hamilton Rating Scale for Depression 
(HAMD: item 1) in patients with treatment resistant depression at baseline, during and 
after 20 weeks of treatment with quetiapine.  
*differences from the baseline scores, p<0.05. 
 
Figure 4. Anxiety scores (mean ± SD) in Hamilton Rating Scale for Depression (HAMD: 
items 10 and 11: anxiety psychosocial and somatic) in patients with treatment resistant 
depression at baseline, during and after 20 weeks of treatment with quetiapine.  
*differences from the baseline scores, p<0.05. 
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Answers to the Reviewer No. 1 
Thank you very much for your comments. 
  
1. It may be useful to note in the methods whether patients were consecutive patients or 
randomized to the study? 
Patients were consequently enrolled into the study. We have stated that in the 
Methods…”This was a prospective, open-labelled, non-comparative, flexible-dosed study 
that lasted 20 weeks….”. However, we have accepted your comment and added…”.. 
Patients (N=18) with major depressive disorder (diagnosis was made using structured 
clinical interview for DSM-IV disorders (American Psychiatric Association 1994) were 
recruited consecutively…. 
 
 
2. It is important to note that whether patients predominantly with sleep disturbances 
(insomnia) and high anxiety scores were selected to the study? 
 
Patients with sleep disturbances and high anxiety scores were not predominantly selected 
for the study. However, these symptoms were pronounced in our sample.  
 
3. It remains unclear from the discussions whether the authors suggest that predictors of 
positive response to quetiapine are insomnia and highly anxious patients? Does the rapid 
onset of improvement correlate with improvement of insomnia? 
 
We can only hypothesize that insomnia and high anxiety scores might be used as 
predictors of the positive response to quetiapine in patients with TRD. However, small 
number of patients, an open studyy design, and the fact that we did not correlate baseline 
insomnia and anxiety scores with the treatment response, do not allow us to draw any 
conclusion regarding their value as the potential predictors of response.  
 
4. Has any of the patients been on any antipsychotic in the past (not current episode)? 
 
No patient has, according to our knowledge, ever received any antipychotic for their 
previous depressive episode-except for low-dose sulpiride (up to 200 mg daily), which 
has been prescribed as an antidepressant drug (. Ref?? Sulpirid i efikasnost u depresiji 
dodati) 
 
5. How was psychosis assessed? BPRS or PANSS? (Exclusion criteria) 
Psychosis was determined as the presence of either delusions or hallucinations in clinical 
interview, as specified in DSM-IV. No BPRS and PANSS were applied.  We have added 
this into Method section...»..presence of psychotic features (determined as the presence of 
either delusions or hallucinations in clinical interview, as specified in DSM-IV);” 
 6. It is important to note that possible pharmacokinetic interactions have been ruled out? 
 
Since quetiapine concentration was not measured, pharmacokinetic interaction with 
antidepressants cannot be ruled-out. We have changed the Limitatations of the study and 
added this comment... «.The study has several limitations such as the small number of 
patients, open-labelled design, and the fact that quetiapine concentration was not 
measured and therefore the pharmacokinetic interaction with antidepressants cannot be 
ruled-out.».. 
 
 
 
 
    
 
Answers to the Reviewer No. 2: 
 
 
1. The MS does not seem very well organised. For example, we are told in the Methods 
section about drop-outs and rate of response when this should be in the Results section. 
The MS needs to be better structured. In addition the Introduction and Discussion should 
be made much more concise. The open design means that the information we can take 
from the study is limited. MIJENJATI TEKST SKRATITI ZA 25 % 
We have accepted your comment and reduced the MS. We have also included the drop-
outs and rate of response into Results. MIJENJATI REZULTATE SKRATITI 
 
 
2. I am unclear what the target dose was. Was it decided individually? Escalating the dose 
of QTP by 50mg each night seems too rapid. What clinical or pharmacological data 
guided the identification of the initial target dose? 
 
The target dose was determined individually, as it was already mentioned in the text, in 
the «Materials and methods». Escalation of the dose od QTP by 50 mg daily was done in 
accordance with the QTP package insert. The target dose was determined according to 
the individual safety and tolerability, and this was also already pointed out in the text, in 
the «Materials and methods». The initial QTP target dose was not determned in advance. 
...» . Quetiapine was added to the current antidepressant treatment according to the usual 
dose-titration recommendation (the starting dosage was 50 mg at bedtime). The dosage 
was increased in 50 mg increments daily, up to the individual target dose. The target dose 
was determined according to the safety and tolerability. The mean quetiapine dose was 
315 ± 109 mg/day…” 
 
 
3. As expected the effects of QTP on sleep and anxiety were fairly rapid. However, the 
effect on depressed mood seems substantially delayed. This is in contrast to most 
augmentation studies with atypicals where the majority of the antidepressant effect is 
seen in the first week of treatment. This needs discussion. Is it because the effect of QTP 
is less specific, perhaps due to natural remission?  
 We have accepted  
 
We agree with your comment. While the QTP effects on sleep and anxiety were fairy 
rapid, the effect on depressed mood was substantially delayed. Therefore, the 
improvement of the depressed mood could also be contributed to the natural remission. 
We did not discuss that since only randomized, placebo-controlled, QTP add-on study, 
could determine whether QTP has a delayed antidepressant efficacy. 
 
4. The plotted graphs presumably reflect study completers. I think that these data will be 
more clinically meaningful if all subjects are included with a last observation carried 
forward (LOCF) analysis. It would also be helpful to know how many subjects met 
criteria for remission (HAM-D <8).    
In the article with  
 Friedman repeated measures one-way analysis of variance (RMANOVA) and Dunnett’s 
test. The treatment effect was evaluated with RMANOVA, and Dunnett’s test compared 
the treatment scores achieved after 1-20 weeks of treatment with the baseline scores. 
Treba izracunati 
 
 
5. When discussing the effects of atypicals on sleep in depression, the papers of Sharpley 
et al (Journal of Clinical Psychiatry 66 (4), pp. 450-454 and Journal of Clinical 
Psychiatry 64 (2), pp. 192-196) seem more relevant than the publications on 
schizophrenia and should be cited.   
 
6. I think Table 1 should contain the data for all 18 subjects. Why is there an excess of 
male subjects? This seems unusual. The HAM-D scores look very high (with a small 
SD). I don't think we need the 50% HAM-D score.      
We accepted your comment and included all  data from 18 patients and used LOCF, and 
therefore had to change all statistics and consequently the results. 
 
The excess of male subjects is simply due to the structure of our Department of 
Biological Psychiatry, where two thirds of hospital beds are occupied with males. 
 
 Reviewer: 3 
Comments of Reviewer for the attention of authors. 
This paper presents novel findings on the use of quetiapine augmentation in treatment-
resistant depression. The study is well-designed and appropriately conducted. The 
findings are novel and relevant. 
Minor: 
1. In the inclusion criteria, indicate the cut-off minimum score on HAMD-17. 
The minimum cut off scores on HAMD 17 was 20. 
 
 
2. In the exclusion criteria, change “psychoactive use disorder” to “drugs of abuse 
disorder”. 
3. On page 9, it is stated that out of 4 drop-outs, 3 were due to “the lack of response to 
quetiapine”. How was this taken in account in data analysis?  
 We have now included all 18 patients into analysis, using LOCF, and therefore had to 
change the results and statistical evaluation of the data. 
 
 
 
 
  
Reviewer 2. 
Pomaknuti drop-outs u sekciju metoda 
Podaci za non-respondere i drop-outs (za LOCF) za 4 pacijenta ( 3 nonsrepondera N1 N2 
i N3 I i 1 droppout jer je imao hypotension kao nuspojavu lijeka i zato je ispao= 
 
 N-1 N-2 N-3 Drop-out 
Gender F M F M 
No of patients 
with at least 1 
suicide attempt 
0 0 1 1 
Duration of 
current 
depressive 
episode 
(months) 
14 12 7 8 
Number of 
antidepressants 
given to threat 
the current 
episode 
4 4 3 3 
HAMD score 
on baseline 
38 36 37 40 
50% reduction 
of the HAMD 
total score 
Not achieved    
Week when a 
50% fall of 
HAMD was 
achieved 
Not achieved    
 
 N-1 N-2 N-3 Drop out 
Insomnia scores 
at baseline and 
on w-1, w-2, w-
3, w-4 
6,5,5-nakon w-
2 prekinuo 
5,5,4,3-nakon 
w-3 prekinuo 
6,4,4-nakon w-
2 prekinuo 
6,4-nakn w-1 
prekinuo 
Depressed 
mood scores 
4,4,4 3,3,4,4 4,3,4 4,4 
Anxiety scores 6,5,5 6,5,6,5 7,5,6 6,5 
 
 
 
 
 
 
  
 
 
 
 
5. U redu je. 
6. Reviewer 3 
1) The cut-off minimal HAMD-17 score was 20. 
2) We change „psychoactive use disorder“ to „drugs of abuse disorder“. 
3) It was added to analysis 
 
